SCHEMBL2519233

SCHEMBL2519233

CC(C)c1cccc(C(C)C)c1N1C(=O)c2c(F)c(F)c(F)c(NC3CCCC3)c2C1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 5/20 0.57
DPP4 P27487 5/20 0.57
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
GNRHR P30968 2/20 0.33
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989683 0.94 ANPEP (0.55) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL13984484 0.84 CRHBP (0.42) ANPEPDPP4MEN1KMT2AUSP2
SCHEMBL2481189 0.82 DPP4 (0.80) ANPEPDPP4NR1H2NR1H3PTGS1
SCHEMBL2477491 0.80 ANPEP (0.61) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL10022913 0.78 ANPEP (0.51) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL2477514 0.78 ANPEP (0.58) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL10022912 0.78 ANPEP (0.50) ANPEPDPP4NR1H2NR1H3KMT2A
SCHEMBL10022911 0.78 ANPEP (0.50) ANPEPDPP4NR1H2NR1H3KMT2A
SCHEMBL2479315 0.77 ANPEP (0.57) ANPEPDPP4NR1H2NR1H3MEN1
SCHEMBL4864907 0.76 ANPEP (0.54) ANPEPDPP4NR1H2NR1H3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US claimed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US claimed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
US-8232299-B2 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof AVIDIN KFT. (HU) 2012-07-31 US disclosed
EP-2373618-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF Avidin KFT (HU) 2011-10-12 EP disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2010-07-22 US disclosed
WO-2008155594-A2 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AVIDIN KFT (HU) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184762-A1 PHTHALIMIDE DERIVATIVES THAT INFLUENCE CELLULAR VESICULAR SYSTEMS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF NSFL1C, LIPC, NPC1L1 ANPEP 4444/4885DPP4 3452/4885NR1H2 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.